key: cord-1010256-so0ws2t0
authors: Torres, Ignacio; Bellido‐Blasco, Juan B.; Gimeno, Concepción; Burgos, Javier S.; Albert, Eliseo; Moya‐Malo, Raúl; Gascó‐Laborda, Juan Carlos; Tornero, Ana; Soriano, Josefa; Meseguer‐Ferrer, Noemí; Martínez‐Serrano, María; Ortíz‐Rambla, Javier; Buj, Helena; Hernández, Noelia; Peiró, Salvador; Salas, Dolores; Limón, Ramón; Vanaclocha, Hermelinda; Sánchez‐Payá, José; Díez‐Domingo, Javier; Comas, Iñaki; González‐Candelas, Fernando; Navarro, David
title: SARS‐CoV‐2 Delta‐variant breakthrough infections in nursing home residents at midterm after Comirnaty® COVID‐19 vaccination
date: 2022-04-27
journal: J Med Virol
DOI: 10.1002/jmv.27799
sha: 7946a25b64c8b548cfc771edea95557032d70079
doc_id: 1010256
cord_uid: so0ws2t0

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Delta variant breakthrough infections in nursing home residents following vaccination with Comirnaty® COVID‐19 vaccine were characterized. In total, 201 participants (median age, 87 years; range, 64–100; 133 female) from two nursing homes in the Valencian community (Spain) were included. SARS‐CoV‐2‐Spike (S) antibody responses were determined by a lateral flow immunocromatography (LFIC) assay and by quantitative electrochemiluminescent assay in LFIC‐negative participants. SARS‐CoV‐2‐S‐IFNγ T cells were enumerated by flow cytometry in 10 participants. Nasopharyngeal SARS‐CoV‐2 RNA loads were quantified by real‐time polymerase chain reaction assays. Vaccine breakthrough COVID‐19 due to the Delta variant occurred in 39 residents (median age, 87 years; range, 69–96; 31 female) at a median of 6.5 months after vaccination (nine requiring hospitalization). Breakthrough infections occurred at a higher rate (p < 0.0001) in residents who had not been previously infected with SARS‐CoV‐2 (naïve) (33/108; 18%) than in those with prior diagnosis of SARS‐CoV‐2 infection (experienced) (6/93; 6.4%), and were more likely (p < 0.0001) to develop in residents who tested negative by LFIC (20/49) at 3 months after vaccination as compared to their LFIC‐positive counterparts (19/142). Among LFIC‐negative residents, a trend towards lower plasma anti‐RBD antibody levels was noticed in those developing breakthrough infection (p = 0.16). SARS‐CoV‐2 RNA loads in nasopharyngeal specimens were lower in SARS‐CoV‐2‐experienced residents (p < 0.001) and in those testing positive by LFIC (p = 0.13). The frequency of SARS‐CoV‐2‐S‐reactive T cells at 3 months was similar in LFIC‐negative residents with (n = 7) or without (n = 3) breakthrough infection. Prior history of SARS‐CoV‐2 infection and detection of S‐reactive antibodies by LFIC at 3 months is associated with a lower risk of Delta‐variant breakthrough infection in nursing home residents at midterm after Comirnaty® COVID‐19 vaccination.

messenger RNA (mRNA) vaccine protection against both asymptomatic infection and COVID-19 has been documented in the general population, healthcare workers, and nursing home residents. [1] [2] [3] [4] [5] This phenomenon is particularly worrisome in the latter collective given their inherent risk of developing severe forms of COVID-19. In a recent study, 4 the adjusted effectiveness of full mRNA vaccination against laboratory-confirmed SARS-CoV-2 infection was reported to drop notably with the emergence of the Delta variant, although the net impact of this variant's involvement could not be discriminated from the potential link to the decline in vaccine-induced immunity. The congregate nature of nursing home residences favors wide exposure of residents to SARS-CoV-2 following outbreak declaration, which potentially allows us to gauge the extent of protection afforded by postvaccination immunity against breakthrough infections. Here, we report on the relationship between SARS-CoV-2 immunity at 3 months after full administration of the Comirnaty ® vaccine (two doses), as assessed in a previous study 6 Personal data from nursing homes and residents were processed in accordance with European data protection regulations. 

We used a previously detailed immunological testing strategy 6 7 Overall, breakthrough infections occurred at a higher rate (p < 0.0001) in residents who had not been previously infected with SARS-CoV-2 (naïve) (33/108; 18%) TORRES ET AL. | 3 than in those who had been (experienced) (6/93; 6.4%): specifically, the relative risk of contracting SARS-CoV-2 breakthrough infection was around two-fold higher in the former than the latter ( Table 1 ). All but one (8/9) hospitalized residents were SARS-CoV-2-naïve.

Overall, SARS-CoV-2 RNA load in NP at time of diagnosis was 6.8 log 10 copies/ml (range, 2.4-9.7). As shown in Figure 1A Table 2) . Testing negative by LFIC resulted in a 2.8-fold increased risk of acquiring breakthrough infection (Table 1) .

Likewise, hospitalized patients tested negative by LFIC more frequently than nonhospitalized residents (p = 0.07) ( As per protocol, residents testing negative by LFIC (n = 49) were assessed for total anti-RBD antibodies ( Table 2) . Antibodies were detectable in 19/20 and 24/29 residents with or without subsequent breakthrough infection (p = 0.20). As shown in Figure 2 , a trend toward lower plasma anti-RBD antibody levels was noticed in residents developing breakthrough infection (p = 0.16).

Among residents developing breakthrough infections, SARS-CoV-2 RNA loads in NP ( Figure 1B) were slightly lower (p = 0.13) in those testing LFIC positive (median, 6.9 log 10 copies/ml; range, 2.4-9.7), compared to participants testing LFIC negative (median, 6.5 log 10 copies/ml; range (2.4-8.7).

Data on T-cell immunity at 3 months were available from 10 LFIC-negative/anti-RBD-positive residents, of whom three contracted vaccine breakthrough infection (none were hospitalized). The rate of detectable responses and the frequency of SARS-CoV-2-Sreactive-IFNγ-producing CD8 + and CD4 + T cells were similar across participants in the two comparison groups ( Table 2 ).

The data reported herein strongly suggest that the strength of Unfortunately, data on SARS-CoV-2-S T-cell immunity at 3 months were only available from a few participants, all of whom tested negative by LFIC and were thus presumed to have suboptimal vaccine responses. 6 We found no differences across participants with or without subsequent breakthrough infection in either detection rate or frequency of SARS-CoV-2-S-reactive CD8 + and CD4 + T cells. Although these data must be interpreted with caution, they seem to suggest that vaccine breakthrough COVID-19 may occur in the face of detectable SARS-CoV-2-S T-cell responses.

Several limitations of the current study must be acknowl- 

The authors declare no conflicts of interest.

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

David Navarro http://orcid.org/0000-0003-3010-4110

Covid-19 breakthrough infections in vaccinated health care workers

Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar

Outbreak of SARS-CoV-2 Infections, Including COVID-19 vaccine breakthrough infections

Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant -National Healthcare Safety Network

Outbreak of SARS-CoV-2 infection in a long-term care facility after COVID-19 BNT162b2 mRNA vaccination

Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty ® COVID-19 vaccine in nursing home residents

Data resource profile: The Valencia Health System Integrated Database (VID)

Initial viral load and decay kinetics of SARS-CoV-2 lineage B.1.1.7 in the upper respiratory tract of adults and children

Association of prior SARS-CoV-2 infection with risk of breakthrough infection following mRNA vaccination in Qatar

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam

Viral loads of Deltavariant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2

Characterisation of vaccine breakthrough infections of SARS-CoV-2 Delta and Alpha variants and within-host viral load dynamics in the community